---
title: "UBS Raises Pfizer, Inc.  TP to USD30, Rating Neutral; Quarterly Results Beat Forecasts and Guidance Raised"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304405180.md"
description: "UBS raised Pfizer's target price to USD30 from USD27, maintaining a Neutral rating. The upgrade follows Q3 results beating forecasts, with revenue of USD16.58 billion and EPS of USD0.87. Management also raised full-year revenue guidance to USD62-64 billion. UBS cited improved results stabilizing core business but noted ongoing patent expiry pressures."
datetime: "2026-11-05T07:28:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304405180.md)
  - [en](https://longbridge.com/en/news/304405180.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304405180.md)
generator: "portal-rs"
---

# UBS Raises Pfizer, Inc.  TP to USD30, Rating Neutral; Quarterly Results Beat Forecasts and Guidance Raised

UBS published a research report stating that Pfizer, Inc. (PFE.US) 's third-quarter results beat expectations, with quarterly revenue of USD16.58 billion, above market expectations of USD15.85 billion. EPS was USD0.87, higher than market expectations of USD0.73. Management raised full-year revenue guidance to between USD62 billion and USD64 billion, with the midpoint of guidance increased by USD1.5 billion from USD61.5 billion to USD63 billion. Multiple projects in the product pipeline continued to advance.

The broker believes the improved results will help stabilize the core business. However, the company still faces patent expiry pressure of about USD15 billion to USD20 billion over the next few years, and whether it can fill the patent gap through 2030 remains to be seen. It expects a key near-term catalyst to be the Phase III data for MEVPRO-1 in second-line metastatic castration-resistant prostate cancer in 1Q27.

The broker raised its TP on Pfizer, Inc. (PFE.US) from USD27 to USD30, corresponding to about 10x to 11x its 2027 EPS forecast, while maintaining a Neutral rating.(gc/da)(Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

### Related Stocks

- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

- [Pfizer Signs Licensing Deal With Starna Therapeutics for Autoimmune Disease Treatments](https://longbridge.com/en/news/305966590.md)
- [Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies](https://longbridge.com/en/news/306119677.md)
- [Datapharm expands SRD Search into France](https://longbridge.com/en/news/305684420.md)
- [Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund](https://longbridge.com/en/news/305354338.md)
- [Blackstone Bankrolls Pfizer’s Weight Loss Drug Trials for Slice of Future Sales](https://longbridge.com/en/news/305334238.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**